Trial management in psychopharmacology. The roles and tasks of an industry physician.

[1]  V. Beral,et al.  MALIGNANT-MELANOMA AND FLUORESCENT LIGHTING - REPLY , 1972 .

[2]  W. Russell.  Doctor and nurse. , 1970, Lancet.

[3]  K. G. Kohlstaedt.  CONDUCTING INVESTIGATIONAL DRUG STUDIES FOR INDUSTRY , 1970, Annals of the New York Academy of Sciences.

[4]  L. Lasagna.  DRUG EVALUATION PROBLEMS IN ACADEMIC AND OTHER CONTEXTS , 1970, Annals of the New York Academy of Sciences.

[5]  R. Fieve,et al.  Three alternatives to the double-blind. , 1969, Archives of general psychiatry.

[6]  D. Engelhardt,et al.  Physician bias and the double-blind. , 1969, Archives of general psychiatry.

[7]  P. Lowinger,et al.  What Makes the Placebo Work?: A Study of Placebo Response Rates , 1969 .

[8]  B. McLaughlin,et al.  Sample size in psychiatric drug research , 1968, Clinical pharmacology and therapeutics.

[9]  P. Leyburn.  A critical look at antidepressant drug trials. , 1967, Lancet.

[10]  M. Shepherd,et al.  Early evaluation of psychotropic drugs in man. A trial that failed. , 1967, Lancet.

[11]  C. Clark,et al.  A method for the rapid determination of the number of patients to include in a controlled clinical trial. , 1966, Lancet.

[12]  R. Lipman,et al.  Neurotics Who Fail to Take their Drugs , 1965, British Journal of Psychiatry.

[13]  E. Hare,et al.  Do psyhiatric out-patients take their drugs? , 1965, British medical journal.

[14]  M. Jacobsen.  The use of Rating Scales in Clinical Research , 1965, British Journal of Psychiatry.

[15]  I. C. Winter.  PROBLEMS IN DRUG DEVELOPMENT AS THEY RELATE TO THE PHARMACEUTICAL INDUSTRY. , 1964, The Journal of New Drugs.

[16]  B. Cromie.  THE FEET OF CLAY OF THE DOUBLE-BLIND TRIAL. , 1963, Lancet.

[17]  T. Hanlon,et al.  Comparative studies of the phenothiazine tranquilizers: methodological and logistical considerations. , 1961, The Journal of nervous and mental disease.

[18]  J. Brown.  The Biological Approach to Bacteriology , 1932, Journal of bacteriology.